SAMSUNG ELECTRONICS SINGAPORE PTE. LTD.
Location
Founded
2020-02-03
Website
Risk Signals
7095 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Electronic Parts and Equipment, Not Elsewhere Classified), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about SAMSUNG ELECTRONICS SINGAPORE PTE. LTD.
Live alerts from global media, monitored by Business Radar
2025-04-29 (chosun.com)
Lucas Bio partners with Samsung Medical Center to develop pediatric cystitis treatment -
Lucas Bio partners with Samsung Medical Center to develop pediatric cystitis treatment Pediatric viral cystitis treatment gains federal support throug
Read more
2025-04-09 (sammyfans.com)
Samsung Galaxy Watch Sleep Apnea detection to be enhanced in major Stanford-led study -
Samsung teams with Stanford University to advance the Galaxy Watch Sleep Apnea detection. The company has inked a research project with Stanford Medicine to initiate an innovative health solution based on its obstructive sleep apnea feature. Earlier, the Galaxy Watch Sleep Apnea detection feature was authorized by the US FDA. Samsung has also rolled out the […]
Read more
2025-04-07 (lifesciencereport.com)
Teva Pharmaceutical and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States -
EPYSQLI® (eculizumab-aagh) is now available to patients living with difficult-to-treat rare diseases like paroxysmal nocturnal hemoglobinuria, atyp...
Read more
2025-04-02 (koreatimes.co.kr)
FDA approves Samsung Bioepis' Epysqli as cost-effective biosimilar to Soliris, offering new hope for patients - The Korea Times
The U.S. Food and Drug Administration (FDA) has approved Samsung Bioepis' Epysqli as a biosimilar to Soliris, one of the most expensive drugs used for treating patients with paroxysmal nocturnal hemog...
Read more
2025-03-24 (corrierenazionale.it)
Osteporosis: Samsung Bioepis gets approval for Denosumab biosimilars -
Osteoporosis: the European Commission has recently granted the marketing of the marketing of Obodence and Xbryk, biosimilar of Denosumab.
Read more
2025-02-25 (koreabiomed.com)
Samsung Bioepis launches Stelara biosimilar in US to expand treatment options < Bio < Article -
Samsung Bioepis said that Pyzchiva, a biosimilar referencing Stelara (ingredient: ustekinumab), is now available in the U.S.Through its commercialization partner Sandoz, Samsung Bioepis has made Pyzchiv available in the U.S. in various formulations, including 45 mg/0.5 mL and 90 mg/mL pre-filled syr
Read more
2025-02-15 (businesswire.com)
Samsung Bioepis Gains European Commission (EC) Approval for Denosumab Biosimilar (OBODENCE™, XBRYK™) | Business Wire
Samsung Bioepis Co., Ltd. today announced that the European Commission (EC) has granted marketing authorization for OBODENCE™ (60mg pre-filled syringe
Read more
2024-09-20 (jamanetwork.com)
Wearable Device–Based Intervention for Promoting Patient Physical Activity After Lung Cancer Surgery: A Nonrandomized Clinical Trial | Surgery | JAMA Network Open | JAMA Network
This nonrandomized clinical trial examines the effects of a wearable-based intervention on physical activity, recovery of cardiopulmonary function, and
Read more
2024-07-22 (globenewswire.com)
FDA Approves Samsung Bioepis' EPYSQLI® (eculizumab-aagh) as a Biosimilar to Soliris (eculizumab)
Samsung Bioepis' eighth biosimilar approved by the U.S. Food and Drug AdministrationEPYSQLI is approved for the treatment of patients with paroxysmal...
Read more
2024-04-22 (nasdaq.com)
Sandoz : Pyzchiva Approved In Europe For Gastroenterology, Dermatology, And Rheumatology Treatments |
(RTTNews) - Sandoz (SDZNY) said that the European Commission has granted marketing authorization for Pyzchiva (biosimilar ustekinumab), developed and registered by Samsung Bioepis. Pyzchiva is approved as a biologic therapy within gastroenterology, dermatology, and rheumatology.
Read more
2024-04-05 (globenewswire.com)
Samsung Bioepis Initiates Phase 3 Clinical Trial for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)
INCHEON, Korea, April 05, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today announced the initiation of Phase 3 clinical trial for SB27, the...
Read more
2024-01-16 (itnonline.com)
Lunit AI Solutions to Power Samsung's X-ray Devices for Advanced Chest Screening
January 16, 2024 — Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced a three-year supply contract with Samsung Electronics (Samsung Healthcare).
Read more